IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Sage Mountain Advisors LLC

Sage Mountain Advisors LLC grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 612 shares of the company’s stock after purchasing an additional 55 shares during the period. Sage Mountain Advisors LLC’s holdings in IDEXX Laboratories were worth $253,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of IDXX. Flossbach Von Storch SE increased its holdings in shares of IDEXX Laboratories by 5,439.3% in the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock valued at $195,696,000 after purchasing an additional 464,791 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of IDEXX Laboratories by 265.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after purchasing an additional 316,048 shares during the period. Seilern Investment Management Ltd acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $113,104,000. Vontobel Holding Ltd. increased its holdings in shares of IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock valued at $173,051,000 after purchasing an additional 198,404 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $71,893,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $412.40 on Thursday. The company has a market cap of $33.54 billion, a PE ratio of 38.65, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The stock’s 50 day simple moving average is $438.09 and its 200-day simple moving average is $448.02. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $550.24. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of research reports. Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, March 7th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley lowered their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.